Prof Thomas Bieber | Singapore General Hospital

Prof Thomas Bieber
Former Chairman and Director, Department of Dermatology and Allergy, University Hospital Bonn, Germany
Founder Bieber Dermatology Consulting

Professor Thomas Bieber is a dermatologist and physician scientist (M.D. and PhD. in immunology) with long lasting experience in academic Dermatology and Allergy as well as a consultant in medical cosmetics and drug development. From 1997 to 2023, he was chairman and director of the department of Dermatology and Allergy at the University Hospital, Bonn, Germany. Along many years of practice in clinical dermatology, basic research activities, drug regulatory affairs (including market access issues) and as consultant for pharmaceutical companies and investors, he built his own kind of “Blue Ocean” with this unique combination of background and expertise. This USP is the foundation for a high-level consultancy in the field of medical cosmetics and drug development strategy.

Session:

17 April 2026, 1015 - 1100hrs, NAK Auditorium, Academia

Presenting Title:

Precision Care in Dermatology and Allergy: Translating Molecular Insights into Clinical Applications
The landscape of atopic dermatitis (AD) management is undergoing a paradigm shift from conventional severity-based assessment to sophisticated molecular profiling approaches that enable precision treatment selection. This evolution raises critical questions about current positioning and future directions in AD therapeutics.

Central to this transformation is our enhanced understanding of Type 2 inflammation pathways, particularly the role of IL-4 and IL-13 cytokines in disease pathogenesis. The development of targeted biologics, represents a milestone in translating molecular insights into tangible clinical benefits. These therapeutic advances demonstrate how mechanistic understanding of inflammatory pathways can be leveraged to achieve improved patient outcomes through targeted intervention strategies.

The concept of the atopic march—the sequential progression from AD to asthma and allergic rhinitis—presents both challenges and opportunities in precision medicine. Emerging evidence suggests that early, targeted intervention in AD may potentially interrupt this disease trajectory, preventing the development of subsequent atopic conditions. This hypothesis underscores the critical importance of interdisciplinary collaboration between dermatology and allergy specialists to optimize patient care across the spectrum of atopic diseases. The successful implementation of precision medicine in AD requires the integration of multiple diagnostic modalities, including biomarker analysis, genomic profiling, and comprehensive clinical phenotyping. The challenge lies in translating these sophisticated research tools into routine clinical practice, making personalized treatment approaches accessible and practical for everyday patient care.

As we advance toward precision medicine in AD management, the field must address fundamental questions regarding optimal patient stratification, biomarker validation, and treatment algorithms. The future of AD therapeutics depends on our ability to seamlessly integrate molecular diagnostics with clinical expertise, ultimately delivering individualized treatment strategies that address the heterogeneous nature of this complex inflammatory disease.

Return to Speakers >